What is Pentadeca Arginate (PDA) used for?

Reported uses include same repair signaling as bpc-157 and marketed as a compounding workaround post-2023 fda action. Evidence strength is rated Experimental — see the evidence section for detail.

How is Pentadeca Arginate (PDA) dosed?

Commonly referenced dosing is 250 – 500 mcg 1–2×/day, typically daily, administered SubQ. This is educational reference only; consult a licensed clinician before use.

What are the side effects of Pentadeca Arginate (PDA)?

Commonly reported side effects include presumed same as bpc-157. This list is not exhaustive.

Pentadeca Arginate (PDA)

§ 01 Overview

Overview

Di-L-arginine salt of BPC-157 marketed by compounding pharmacies after the 2023 Category-2 restriction. Functionally identical sequence.

No peer-reviewed literature under the 'pentadeca arginate' name; the data is all BPC-157 literature.

§ 02 Mechanism

Mechanism of action

Pentadeca arginate is the same 15-amino-acid sequence as BPC-157 paired with an arginate counter-ion, claimed to improve gastric stability versus the acetate salt. Biologically it acts as BPC-157 does: angiogenesis, nitric oxide, growth factor signaling.

01Same repair signaling as BPC-157
02Marketed as a compounding workaround post-2023 FDA action

§ 03 Dosing

Dosing protocol

Standard Protocol

Dose Range: 250 – 500 mcg 1–2×/day
Route: SubQ
Frequency: Daily
Cycle: 4–6 weeks

§ 04 Evidence

Evidence & research

Experimental

No peer-reviewed literature under the 'pentadeca arginate' name; the data is all BPC-157 literature.

FDA Status

Not FDA-approved. Regulatory status mirrors BPC-157: on the 503A Negative List.

§ 05 Stacks

Common stacks

BPC-157

Same peptide, different salt

§ 07 Sourcing

Sourcing & supply

Regulatory status

Restricted from compounding

Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09 Safety

Safety & side effects

Side effects

01Presumed same as BPC-157

Contraindications

None specified.

§ 10 Questions

Pentadeca Arginate (PDA) FAQ

What is Pentadeca Arginate (PDA)?: Di-L-arginine salt of BPC-157 marketed by compounding pharmacies after the 2023 Category-2 restriction. Functionally identical sequence. Pentadeca arginate is the same 15-amino-acid sequence as BPC-157 paired with an arginate counter-ion, claimed to improve gastric stability versus the acetate salt. Biologically it acts as BPC-157 does: angiogenesis, nitric oxide, growth factor signaling.
What is Pentadeca Arginate (PDA) used for?: Reported uses include same repair signaling as bpc-157 and marketed as a compounding workaround post-2023 fda action. Evidence strength is rated Experimental — see the evidence section for detail.
How is Pentadeca Arginate (PDA) dosed?: Commonly referenced dosing is 250 – 500 mcg 1–2×/day, typically daily, administered SubQ. This is educational reference only; consult a licensed clinician before use.
What are the side effects of Pentadeca Arginate (PDA)?: Commonly reported side effects include presumed same as bpc-157. This list is not exhaustive.
Is Pentadeca Arginate (PDA) legal?: Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales. FDA status: Not FDA-approved. Regulatory status mirrors BPC-157: on the 503A Negative List..

§ 11 References

Selected references

01
Sikirić — BPC-157 sequence origin
PMID: 9403784
02
Diagen patent — arginate salt
WO2014142764A1